These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 19337536)
21. Psoriasis and cardiovascular disorders. Frieder J; Ryan C G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099 [TBL] [Abstract][Full Text] [Related]
22. Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. Teklu M; Zhou W; Kapoor P; Patel N; Dey AK; Sorokin AV; Manyak GA; Teague HL; Erb-Alvarez JA; Sajja A; Abdelrahman KM; Reddy AS; Uceda DE; Lateef SS; Shanbhag SM; Scott C; Prakash N; Svirydava M; Parel P; Rodante JA; Keel A; Siegel EL; Chen MY; Bluemke DA; Playford MP; Gelfand JM; Mehta NN J Am Acad Dermatol; 2021 May; 84(5):1329-1338. PubMed ID: 33383084 [TBL] [Abstract][Full Text] [Related]
23. [Psoriasis and cardiovascular disease]. Torres T; Sales R; Vasconcelos C; Selores M Acta Med Port; 2013; 26(5):601-7. PubMed ID: 24192101 [TBL] [Abstract][Full Text] [Related]
24. Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges. Pannu S; Rosmarin D Am J Clin Dermatol; 2021 May; 22(3):293-300. PubMed ID: 33586126 [TBL] [Abstract][Full Text] [Related]
25. Psoriasis as a systemic disease. Grozdev I; Korman N; Tsankov N Clin Dermatol; 2014; 32(3):343-50. PubMed ID: 24767182 [TBL] [Abstract][Full Text] [Related]
26. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. Hu SC; Lan CE Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29065479 [TBL] [Abstract][Full Text] [Related]
27. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A Front Immunol; 2018; 9():1668. PubMed ID: 30150978 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Coumbe AG; Pritzker MR; Duprez DA Am J Med; 2014 Jan; 127(1):12-8. PubMed ID: 24161194 [TBL] [Abstract][Full Text] [Related]
29. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Späh F Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910 [TBL] [Abstract][Full Text] [Related]
30. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Carrascosa JM; Rocamora V; Fernandez-Torres RM; Jimenez-Puya R; Moreno JC; Coll-Puigserver N; Fonseca E Actas Dermosifiliogr; 2014; 105(1):31-44. PubMed ID: 23177976 [TBL] [Abstract][Full Text] [Related]
31. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. Kim J; Tomalin L; Lee J; Fitz LJ; Berstein G; Correa-da Rosa J; Garcet S; Lowes MA; Valdez H; Wolk R; Suarez-Farinas M; Krueger JG J Invest Dermatol; 2018 Feb; 138(2):273-281. PubMed ID: 28927890 [TBL] [Abstract][Full Text] [Related]
32. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Mehta NN; Azfar RS; Shin DB; Neimann AL; Troxel AB; Gelfand JM Eur Heart J; 2010 Apr; 31(8):1000-6. PubMed ID: 20037179 [TBL] [Abstract][Full Text] [Related]
33. Psoriasis and cardiovascular comorbidities with emphasis in Asia. Chu TW; Tsai TF G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582 [TBL] [Abstract][Full Text] [Related]